Control of an outbreak due to an adamantane-resistant strain of influenza A (H3N2) in a chronic care facility

Infection

Volumn 36, Issue 5, 2008, Pages 458-462

  Cohen, N J ^a,b   Morita, J Y ^a   Plate, D K ^a   Jones, R C ^a   Simon, M T ^c   Nawrocki, J ^d   Siston, A M ^a   Gerber, S I ^a  

^a CHICAGO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Misericordia/Heart of Mercy Center   (United States)

^d ILLINOIS DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; AMANTADINE; ASPARAGINE; INFLUENZA VACCINE; PROTEIN M2; RIMANTADINE; SERINE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ARTICLE; CHILD; CLINICAL PRACTICE; CONTROLLED STUDY; HEALTH CARE FACILITY; HUMAN; INFECTION CONTROL; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MUTATION; NEUROLOGIC DISEASE; PATIENT IDENTIFICATION; PYROSEQUENCING; RETROSPECTIVE STUDY; SEASON; STRAIN IDENTIFICATION; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS RESISTANCE; VIRUS STRAIN;

ADAMANTANE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; FEMALE; HUMANS; INFECTION CONTROL; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MALE; MUTATION; NURSING HOMES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 56549104347     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-008-7295-9     Document Type: Article

References (36)

1. Patriarca PA, Weber JA, Parker RA, Orenstein WA, Hall WN, Kendal AP, Schonberger LB: Risk factors for outbreaks of influenza in nursing homes. A case-control study. Am J Epidemiol 1986; 124: 114-119.
2. Sugaya N, Kusumoto N, Suzuki Y, Nerome R, Nerome K: Large sequential outbreaks caused by influenza A (H3N2) and B viruses in an institution for the mentally handicapped. J Med Virol 1996; 50: 120-125.
3. Centers for Disease Control and Prevention (CDC). Influenza A - Florida and Tennessee, July-August 1998, and virologic surveillance of influenza, May-August 1998. MMWR Morb Mortal Wkly Rep 1998; 47: 756-759.
4. Gerber SI, Erdman DD, Pur SL, Diaz PS, Segreti J, Kajon AE, Belkengren RP, Jones RC: Outbreak of adenovirus genome type 7d2 infection in a pediatric chronic-care facility and tertiary-care hospital. Clin Infect Dis 2001; 32: 694-700.
5. Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, Black S, Shinefield H, Fukuda K: Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000; 342: 232-239.
6. Neuzil KM, Wright PF, Mitchel EF Jr, Griffin MR: The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr 2000; 137: 856-864.
7. Keren R, Zaoutis TE, Bridges CB, Herrera G, Watson BM, Wheeler AB, Licht DJ, Luan XQ, Coffin SE: Neurologic and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection. JAMA 2005; 294: 2188-2194.
8. Bhat N, Wright JG, Broder KR, Murray EL, Greenberg ME, Glover MJ, Likos AM, Posey DL, Klimov A, Lindstrom SE, Balish A, Medina MJ, Wallis TR, Guarner J, Paddock CD, Shieh WJ, Zaki SR, Sejvar JJ, Shay DK, Harper SA, Cox NJ, Fukuda K, Uyeki TM; Influenza Special Investigations Team: Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med 2005; 353: 2559-2567.
9. Quach C, Piché-Walker L, Platt R, Moore D: Risk factors associated with severe influenza infections in childhood: implications for vaccine strategy. Pediatrics 2003; 112: e197-e201.
10. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC): Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54(RR-8): 1-40.
11. Atkinson WL, Arden NH, Patriarca PA, Leslie N, Lui KJ, Gohd R: Amantadine prophylaxis during an institutional outbreak of type A (H1N1) influenza. Arch Intern Med 1986; 146: 1751-1756.
12. Douglas RG Jr: Prophylaxis and treatment of influenza. N Engl J Med 1990; 322: 443-450.
13. Gravenstein S, Davidson HE: Current strategies for management of influenza in the elderly population. Clin Infect Dis 2002; 35: 729-737.
14. Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, Yousuf H, Regnery H, Klimov AI, Cox NJ, Whimbey E: Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26: 1418-1424.
15. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S: Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991; 35: 1741-1747.
16. Ziegler T, Hemphill ML, Ziegler ML, Perez-Oronoz G, Klimov AI, Hampson AW, Regnery HL, Cox NJ: Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect Dis 1999; 180: 935-939.
17. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ, Klimov AI: Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366: 1175-1181.
18. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI: Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295: 891-894.
19. Centers for Disease Control and Prevention (CDC). High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines foruse of antiviral agents - United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep 2006; 55: 44-46.
20. Bridges CB, Kuehnert MJ, Hall CB: Transmission of influenza: implications for control in health care settings. Clin Infect Dis 2003; 37: 1094-1101.
21. Hall CB, Douglas RG Jr: Nosocomial influenza infection as a cause of intercurrent fevers in infants. Pediatrics 1975; 55: 673-677.
22. Hall CB, Douglas RG Jr, Geiman JM, Meagher MP: Viral shedding patterns of children with influenza B infection. J Infect Dis 1979; 140: 610-613.
23. Frank AL, Taber LH, Wells CR, Wells JM, Glezen WP, Paredes A: Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis 1981; 144: 433-441.
24. Brocklebank JT, Court SD, McQuillin J, Gardner PS: Influenza-A infection in children. Lancet 1972; 2: 497-500.
25. Blumberg EA, Albano C, Pruett T, Isaacs R, Fitzpatrick J, Bergin J, Crump C, Hayden FG: The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996; 22: 295-302.
26. Dorrell L, Hassan I, Marshall S, Chakraverty P, Ong E: Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers. Int J STD AIDS 1997; 8: 776-779.
27. McElhaney JE, Beattie BL, Devine R, Grynoch R, Toth EL, Bleackley RC: Age-related decline in interleukin 2 production in response to influenza vaccine. J Am Geriatr Soc 1990; 38: 652-658.
28. Groothuis JR, Lehr MV, Levin MJ: Safety and immunogenicity of a purified haemagglutinin antigen in very young high-risk children. Vaccine 1994; 12: 139-141.
29. Park CL, Frank AL, Sullivan M, Jindal P, Baxter BD: Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Pediatrics 1996; 98: 196-200.
30. Pearson ML, Bridges CB, Harpet SA; Healthcare Infection Control Practices Advisory Committee (HICPAC); Advisory Committee on Immunization Practices (ACIP): Influenza vaccination of healthcare personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55 (RR-2): 1-16.
31. Schilling M, Gravenstein S, Drinka P, Cox N, Krause P, Povinelli L, Shult P: Emergence and transmission of amantadine-resistant influenza A in a nursing home. J Am Geriatr Soc 2004; 52: 2069-2073.
32. Lee C, Loeb M, Phillips A, Nesbitt J, Smith K, Fearon M, McArthur MA, Mazzulli T, Li Y, McGeer A: Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control Hosp Epidemiol 2000; 21: 700-704.
33. Mast EE, Harmon MW, Gravenstein S, Wu SP, Arden NH, Circo R, Tyszka G, Kendal AP, Davis JP: Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991; 134: 988-997.
34. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W: Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321: 1696-1702.
35. Belshe RB, Burk B, Newman F, Cerruti RL, Sim IS: Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis 1989; 159: 430-435.
36. Houck P, Hemphill M, LaCroix S, Hirsh D, Cox N: Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug use. Arch Intern Med 1995; 155: 533-537.